Recombinant adeno-associated virus: Formulation challenges and strategies for a gene therapy vector

Current Opinion in Drug Discovery and Development

Volumn 6, Issue 2, 2003, Pages 174-178

  Wright, J Fraser ^a   Qu, Guang ^a   Tang, Chunlin ^a   Sommer, Jurg M ^a  

^a Avigen Inc   (United States)

Author keywords

AAV vectors; Excipient; Formulation; Gene therapy; Stability

Indexed keywords

ADENOVIRUS VECTOR; GENE PRODUCT;

ADENO ASSOCIATED VIRUS; DRUG BINDING; DRUG EFFICACY; DRUG FORMULATION; DRUG PURIFICATION; DRUG SAFETY; DRUG STABILITY; DRUG STORAGE; GENE EXPRESSION; GENE THERAPY; IMMUNE RESPONSE; OXIDATION; PROTEIN AGGREGATION; PROTEIN DEGRADATION; REVIEW;

ADENOVIRIDAE; ADSORPTION; ANIMALS; CHEMISTRY, PHARMACEUTICAL; DRUG STABILITY; GENE THERAPY; GENETIC VECTORS; HUMANS;

EID: 0037344731     PISSN: 13676733     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (50)

1. Berns KI: Parvoviridea: The viruses and their replication. In: Fields Virology, 3rd Edition. Fields BN, Knipe DM, Howley PM, Chanock RM, Melnick JL, Monath TP, Roizman B, Straus SE (Eds). Lippincott Raven Press, Philadelphia, PA, USA (1996):2173-2197.
2. Srivastava A, Lusby EW, Berns KI: Nucleotide sequence and organization of the adeno-associated virus 2 genome. J Virol (1983) 45:555-564.
3. Xiao X, Li J, Samulski RJ: Production of high-titer recombinant adenovirus-associated virus vectors in the absence of helper adenovirus. J Virol (1998) 72:2224-2232.
4. Buller RM, Janik JE, Sebring ED, Rose JA: Herpes simplex virus types 1 and 2 completely help adeno-associated virus replication. J Virol (1981) 40:241-247.
5. Weindler FW, Heilbronn R: A subset of herpes simplex virus replication genes provides helper functions for productive adeno-associated virus replication. J Virol (1991) 65:2476-2483.
6. Samulski RJ, Berns KI, Tan M, Muzyczka N: Cloning of adeno-associated virus into pBR322: Rescue of intact virus from the recombinant plasmid in human cells. Proc Natl Acad Sci USA (1982) 79:2077-2081.
7. Muzyczka N: Use of adeno-associated virus as a general transduction vector for mammalian cells. Curr Top Microbiol Immunol (1992) 185:97-129.
8. Flotte TR, Afione SA, Conrad C, McGrath SA, Solow R, Oka H, Zeitlin PL, Guggino WB, Carter BJ: Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA (1993) 90:10613-10617.
9. Snyder RO, Maio CH, Patijn GA, Spratt SK, Danos O, Nagy D, Gown AM, Winther B, Meuse L, Cohen LK et al: Persistent and therapeutic concentrations of human Factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet (1997) 16:270-276.
10. Clark KR, Sferra TJ, Johnson PR: Recombinant adeno-associated viral vectors mediated long-term transgene expression in muscle. Hum Gene Ther (1997) 8:659-669.
11. McCown TJ, Xiao X, Li J, Breese GR, Samulski RJ: Differential and persistent expression patterns of CNS gene transfer by an adeno-associated virus (AAV) vector. Brain Res (1996) 713:99-107.
12. Ali RR, Sarra GM, Stephens C, Alwis MD, Bainbridge JW, Munro PM, Fauser S, Reichel MB, Kinnon C, Hunt DM et al: Restoration of photoreceptor ultrastructure and function in retinal degeneration slow mice by gene therapy. Nat Genet (2000) 25:306-310.
13. Dudus L, Anand V, Acland GM, Chen SJ, Wilson JM, Fisher KJ, Maguire AM, Bennett J: Persistent transgene product in retina, optic nerve and brain after intraocular injection of rAAV. Vision Res (1999) 39:2545-2553.
14. Chirmule N, Xiao W, Truneh A, Schnell MA, Hughes JV, Zoltick P, Wilson JM: Humoral immunity to adeno-associated virus type 2 vectors following administration to murine and nonhuman primate muscle. J Virol (2000) 74:2420-2425.
15. Hernandez YJ, Wang J, Kearns WG, Loiler S, Poirier A, Flotte TR: Latent adeno-associated virus infection elicits humoral but not cell-mediated immune responses in a nonhuman primate model. J Virol (1999) 73:8549-8558.
16. Herzog RW, Yang EY, Couto LB, Hagstrom JN, Elwell D, Fields PA, Burton M, Bellinger DA, Read MS, Brinkhous KM et al: Long-term correction of canine hemophilia B by gene transfer of blood coagulation Factor IX mediated by adeno-associated viral vector. Nat Med (1999) 5:56-63. AAV vectors administered via intramuscular injection are capable of mediating long-term expression of therapeutic levels of Factor IX in an immunocompetent, large animal model.
17. Snyder RO, Miao C, Meuse L, Tubb J, Donahue BA, Lin HF, Stafford DW, Patel S, Thompson AR, Nichols T et al: Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nat Med (1999) 5:64-70. AAV vectors administered via hepatic blood vessels are capable of mediating long-term expression of therapeutic levels of Factor IX in an immunocompetent, large animal model.
18. Couto L, Scallan C, Jiang H, Qian X, Patarroyo-White S, Parker A, Liu T, Chen H, Powell S, Wright F, Tinlin S, Webster S, Lillicrap D, Arruda V, High K, Kay M, McClelland A: Hemophilia A gene therapy in mouse and dog models using an AAV-FVIII vector. Blood (2002) 100:Abs 431.
19. Davidson BL, Stein CS, Heth JA, Martins I, Kotin RM, Derksen TA, Zabner J, Ghodsi A, Chiorini JA: Recombinant adeno-associated virus type 2, 4, and 5 vectors: Transduction of variant cell types and regions in the mammalian central nervous system. Proc Natl Acad Sci USA (2000) 97:3428-3432.
20. Rutledge EA, Halbert CL, Russell DW: Infectious clones and vectors derived from adeno-associated virus (AAV) serotypes other than AAV type 2. J Virol (1998) 72:309-319.
21. Chiorini JA, Kim F, Yang L, Kotin RM: Cloning and characterization of adeno-associated virus type 5. J Virol (1999) 73:1309-1319.
22. Xiao W, Chirmule N, Berta SC, McCullough B, Gao G, Wilson JM: Gene therapy vectors based on adeno-associated virus type 1. J Virol (1999) 73:3994-4003.
23. Rabinowitz JE, Rolling F, Li C, Conrath H, Xiao W, Xiao X, Samulski RJ: Cross-packaging of a single adeno-associated virus (AAV) type 2 vector genome into multiple AAV serotypes enables transduction with broad specificity. J Virol (2002) 76:791-801.
24. Kay MA, Manno CS, Ragni MV, Larson PJ, Couto LB, McClelland A, Glader B, Chew AJ, Tai SJ, Herzog RW et al. Evidence for gene transfer and expression of Factor IX in haemophilia B patients treated with an AAV vector. Nat Genet (2000) 24:257-261.
25. Kay MA, High K, Glader B, Manno CS, Hutchinson S, Dake M, Razavi M, Kaye R, Arruda VR, Herzog R et al: A phase I/II clinical trial for liver-directed AAV-mediated gene transfer for severe hemophilia B. Blood (2002) 100:Abs 426. The transient expression of therapeutic levels of human Factor IX in a recipient following administration of rAAV via hepatic artery is described.
26. Croyle MA, Cheng X, Wilson JM: Development of formulations that enhance physical stability of viral vectors for gene therapy. Gene Ther (2001) 8:1281-1290. A systematic evaluation of the effects of varying excipients, buffers and storage conditions on the activity of AAV and adenovirus, is presented. Frozen and non-frozen liquid vector stabilities are discussed, and preliminary work evaluating lyophilization of viral vectors is described.
27. Xu R, Mastokov M, Yang P-H, Ma H, Tse L, Chen Q, Kung H, During M: In vivo study on stability of recombinant adeno-associated viral vector stocks. Mol Therapy (2002) 5:S52.
28. Huang J, Gao G, Croyle M, Kurtzman G, Conceicao C, Baradet T, Wilson J: Aggregation of AAV vectors, its impact on liver directed gene transfer and development of vector formulations to prevent and dissolve aggregation and enhance gene transfer efficiency. Mol Therapy (2000) 1:S286.
29. Sommer JM: Adeno-associated virus (AAV): Stability of gene therapy vector. IBC Formulation Strategies for Biopharmaceuticals Conference, Miami, FL, USA (2002).
30. Qu G, Zhen J, Nguyen K, Colosi P, Bahr-Davidson J, Wright F, McClelland A: Scale-up of recombinant adeno-associated virus gene therapy vector production and purification. Mol Therapy (2000) 1:S284.
31. Gao G, Qu G, Burnham MS, Huang J, Chirmule N, Joshi B, Yu QC, Marsh JA, Conceicao CM, Wilson JM: Purification of recombinant adeno-associated virus vectors by column chromatography and its performance in vivo. Hum Gene Ther (2000) 11:2079-2091.
32. Clark KR, Liu X, McGrath JP, Johnson PR: Highly purified recombinant adeno-associated virus vectors are biologically active and free of detectable helper and wild-type viruses. Hum Gene Ther (1999) 10:1031-1039.
33. Zolotukhin S, Byme BJ, Mason E, Zolotukhin I, Potter M, Chesnut K, Summerford C, Samulski RJ, Muzyczka N: Recombinant adeno-associated virus purification using novel methods improves infectious titer and yield. Gene Ther (1999) 6:973-985.
34. Kaludov N, Handelman B, Chiorini JA: Scalable purification of adeno-associated virus type 2, 4, or 5 using ion-exchange chromatography. Hum Gene Ther (2002) 13:1235-1243.
35. Kronenberg S, Kleinschmidt JA, Bottcher B: Electron cryo-microscopy and image reconstruction of adeno-associated virus type 2 empty capsids. EMBO Rep (2001) 2:997-1002.
36. Gomall AG, Goldberg DM: Hepatobiliary disorders. In: Applied Biochemistry of Clinical Disorders. Gomall AG (Ed), Harper and Row, Hagerstown, MD, USA (1980):164-192.
37. Croyle MA, Chirmule N, Gao G-P, Qu G, Wilson JM: Stealth viruses: Novel vectors that evade the immune response and allow for significant levels of gene expression upon readministration. Mol Therapy (2000) 1:S183.
38. Adadevoh K, Croyle M, Malarme D, Bonfils E, Bowe MA: A short-term field use and shipping stability study of a wild type Ad5 adenoviral reference material. BioProcessing (2002):62-69.
39. Sommer J, Sanftner L, Feng L, Suzuki B, Zhen Z, Powell S, Wright F, McClelland A, Cunningham J: Optimal recovery of AAV-AADC vector from Teflon catheters using Polysorbate 80 or Pluronic F68. Mol Therapy (2002) 5:S251.
40. Summerford C, Samulski RJ: Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type-2 virions. J Virol (1998) 72:1438-1445.
41. Qing K, Mah C, Hansen J, Zhou S, Dwarki V, Srivastava A: Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nat Med (1999) 5:71-77.
42. Gao GP, Alvira MR, Wang L, Calcedo R, Johnston J, Wilson JM: Novel adeno-associated viruses from rhesus monkeys as vectors for human gene therapy. Proc Natl Acad Sci USA (2002) 99: 11854-11859. Isolation and characterization of novel AAVs with the potential for higher transduction efficiency and reduced potential for recognition by pre-existing antibodies are described.
43. Vieira A, Cheng X, Bergelson J, Wilson J, Croyle M: Transduction efficiency of PEGylated viral vectors is enhanced in receptor independent manner. Mol Therapy (2001) 3:S359.
44. 2 antibody. Nat Biotechnol (1999) 17:181-186.
45. Shi W, Arnold GS, Bartlett JS: Insertional mutagenesis of the adeno-associated virus type 2 (AAV2) capsid gene and generation of AAV2 vectors targeted to alternative cell-surface receptors. Hum Gene Ther (2001) 12:1697-1711.
46. Ponnazhagan S, Mahendra G, Kumar S, Thompson JA, Castillas M Jr: Conjugate-based targeting of recombinant adeno-associated virus type 2 vectors by using avidin-linked ligands. J Virol (2002) 76:12900-12907.
47. Xie Q, Bu W, Bhatia S, Hare J, Somasundaram T, Azzi A, Chapman MS: The atomic structure of adeno-associated virus (AAV-2), a vector for human gene therapy. Proc Natl Acad Sci USA (2002) 99:10405-10410.
48. Croyle, MA, Chirmule N, Zhang Y, Wilson JM: 'Stealth' adenoviruses blunt cell-mediated and humoral immune responses against the virus and allow for significant gene expression upon readministration in the lung. J Virol (2001) 75:4792-4801. The modification of adenovirus with various monomethoxy-PEGs is presented. In vivo administration resulted in reduced inflammatory cytokine production (T-helper 1-specific) and extended gene expression relative to non-modified vectors.
49. Croyle MA, Chirmule N, Zhang Y, Wilson JM: PEGylation of E1-deleted adenovirus vectors allows significant gene expression following readministration to liver. Hum Gene Ther(2002) 13:1887-1900.
50. Moskalenko M, Chen L, van Roey M, Donahue BA, Snyder RO, McArthur JG, Patel SD: Epitope mapping of human anti-adeno- associated virus type 2 neutralizing antibodies: Implications for gene therapy and virus structure. J Virol (2000) 74:1761-1766.